RAGE signalling in obesity and diabetes: focus on the adipose tissue macrophage

References

• Schmidt AM. RAGE and implications for the pathogenesis and treatment of cardiometabolic disorders – spotlight on the macrophage. Arterioscler Thromb Vasc Biol. 2017;37(4):613–621.
   PubMed Web of Science ®Google Scholar
• Boyer F, Vidot JB, Dubourg AG, et al. Oxidative stress and adipocyte biology: focus on the role of AGEs. Oxid Med Cell Longev. 2015;2015:534873.
   PubMed Web of Science ®Google Scholar
• Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond). 2011;121(2):43–55.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang L, Zhang S, et al. HMGB1, an innate alarmin, plays a critical role in chronic inflammation of adipose tissue in obesity. Mol Cell Endocrinol. 2017;454:103–111.
   PubMed Web of Science ®Google Scholar
• Reynaert NL, Gopal P, Rutten EPA, et al. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. Int J Biochem Cell Biol. 2016;81(Pt B):403–418.
   PubMedGoogle Scholar
• Xie J, Méndez JD, Méndez-Valenzuela V, et al. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013;25(11):2185–2197.
   PubMed Web of Science ®Google Scholar
• Asadipooya K, Lankarani KB, Raj R, et al. RAGE is a potential cause of onset and progression of nonalcoholic fatty liver disease. Int J Endocrinol. 2019;2019:2151302.
   PubMed Web of Science ®Google Scholar
• Strieder-Barboza C, Baker NA, Flesher CG, et al. Advanced glycation end-products regulate extracellular matrix-adipocyte metabolic crosstalk in diabetes. Sci Rep. 2019;9(1):19748.
   PubMedGoogle Scholar
• Egaña-Gorroño L, López-Díez R, Yepuri G, et al. Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models. Front Cardiovasc Med. 2020;7:37.
   PubMed Web of Science ®Google Scholar
• Monden M, Koyama H, Otsuka Y, et al. Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. Diabetes. 2013;62(2):478–489.
   PubMed Web of Science ®Google Scholar
• Song F, Hurtado Del Pozo C, Rosario R, et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes. 2014;63(6):1948–1965.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Yamakuchi M, Biswas KK, et al. HMGB1 is secreted by 3T3-L1 adipocytes through JNK signaling and the secretion is partially inhibited by adiponectin. Obesity (Silver Spring). 2016;24(9):1913–1921.
   PubMed Web of Science ®Google Scholar
• Gunasekaran MK, Viranaicken W, Girard AC, et al. Inflammation triggers high mobility group box 1 (HMGB1) secretion in adipose tissue, a potential link to obesity. Cytokine. 2013;64(1):103–111.
   PubMed Web of Science ®Google Scholar
• Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring). 2006;14(Suppl 5):242s–249s.
   PubMedGoogle Scholar
• Catrysse L, van Loo G. Adipose tissue macrophages and their polarization in health and obesity. Cell Immunol. 2018;330:114–119.
   PubMed Web of Science ®Google Scholar
• Miranda ER, Fuller KNZ, Perkins RK, et al. Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health. Nutr Metab Cardiovasc Dis. 2018;28(11):1155–1165.
   PubMed Web of Science ®Google Scholar
• Engin AB. Adipocyte-macrophage cross-talk in obesity. Adv Exp Med Biol. 2017;960:327–343.
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830.
   PubMed Web of Science ®Google Scholar
• Ni Y, Ni L, Zhuge F, et al. Adipose tissue macrophage phenotypes and characteristics: the key to insulin resistance in obesity and metabolic disorders. Obesity (Silver Spring). 2020;28(2):225–234.
   PubMed Web of Science ®Google Scholar
• Byun K, Yoo Y, Son M, et al. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. Pharmacol Ther. 2017;177:44–55.
   PubMed Web of Science ®Google Scholar
• Xu Y, Toure F, Qu W, et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem. 2010;285(30):23233–23240.
   PubMed Web of Science ®Google Scholar
• Gaens KH, Goossens GH, Niessen PM, et al. Nε-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol. 2014;34(6):1199–1208.
   PubMed Web of Science ®Google Scholar
• Hudson BI, Lippman ME. Targeting RAGE signaling in inflammatory disease. Annu Rev Med. 2018;69:349–364.
   PubMed Web of Science ®Google Scholar
• Burstein AH, Grimes I, Galasko DR, et al. Effect of TTP488 in patients with mild to moderate Alzheimer’s disease. BMC Neurol. 2014;14:12.
   PubMedGoogle Scholar